The University of Southampton
University of Southampton Institutional Repository

Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin

Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin
Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin
OBJECTIVE: To determine if Meglumine-Eicosapentaenoic Acid (MeEPA) acts synergistically with epirubicin and mitomycin to enhance cytotoxicity towards bladder cancer cell lines in vitro.

MATERIALS AND METHODS: Bladder cancer cells were exposed to MeEPA in combination with epirubicin or mitomycin. Residual viable cell biomass was estimated with the methyl-thiazoldiphenyl tetrazolium (MTT) assay following drug exposure. Drug interaction was analysed using median effect analysis to determine levels of synergism.

RESULTS: Most combinations of MeEPA with both epirubicin and mitomycin showed a high-level of synergism. At high doses, drug precipitation adversely affected MTT assay analysis suggesting antagonism of action. However, the predominant pattern was of synergism for most dose combinations tested.

CONCLUSION: Bladder cancer treated by endoscopic resection alone is subject to high recurrence rates. Post-operative intravesical instillation of epirubicin and mitomycin can halve recurrence rates, but there is no evidence that disease progression to invasive bladder cancer is altered. Thus, optimisation of current treatment strategies is required. The anti-tumour activity of fatty acids is well established and MeEPA is a new, soluble formulation with the potential to enhance intravesical drug efficacy.
367-373
Mackie, S.J.
c5c45fba-87e6-4500-812c-ecd8fdbc8989
Sharma, D.M.
d235d81b-b8e1-41d7-976a-1301c4fa9fee
Cooper, A.J.
8a21c297-eda3-4479-8e81-1de258c8e2a1
Harris, N.M.
39ad8cbe-4ca3-438c-b496-ee2e805382be
Lwaleed, B.A.
e7c59131-82ad-4a14-a227-7370e91e3f21
Mackie, S.J.
c5c45fba-87e6-4500-812c-ecd8fdbc8989
Sharma, D.M.
d235d81b-b8e1-41d7-976a-1301c4fa9fee
Cooper, A.J.
8a21c297-eda3-4479-8e81-1de258c8e2a1
Harris, N.M.
39ad8cbe-4ca3-438c-b496-ee2e805382be
Lwaleed, B.A.
e7c59131-82ad-4a14-a227-7370e91e3f21

Mackie, S.J., Sharma, D.M., Cooper, A.J., Harris, N.M. and Lwaleed, B.A. (2006) Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin. Prostaglandins, Leukotrienes and Essential Fatty Acids, 75 (6), 367-373. (doi:10.1016/j.plefa.2006.07.002). (PMID:16930970)

Record type: Article

Abstract

OBJECTIVE: To determine if Meglumine-Eicosapentaenoic Acid (MeEPA) acts synergistically with epirubicin and mitomycin to enhance cytotoxicity towards bladder cancer cell lines in vitro.

MATERIALS AND METHODS: Bladder cancer cells were exposed to MeEPA in combination with epirubicin or mitomycin. Residual viable cell biomass was estimated with the methyl-thiazoldiphenyl tetrazolium (MTT) assay following drug exposure. Drug interaction was analysed using median effect analysis to determine levels of synergism.

RESULTS: Most combinations of MeEPA with both epirubicin and mitomycin showed a high-level of synergism. At high doses, drug precipitation adversely affected MTT assay analysis suggesting antagonism of action. However, the predominant pattern was of synergism for most dose combinations tested.

CONCLUSION: Bladder cancer treated by endoscopic resection alone is subject to high recurrence rates. Post-operative intravesical instillation of epirubicin and mitomycin can halve recurrence rates, but there is no evidence that disease progression to invasive bladder cancer is altered. Thus, optimisation of current treatment strategies is required. The anti-tumour activity of fatty acids is well established and MeEPA is a new, soluble formulation with the potential to enhance intravesical drug efficacy.

Full text not available from this repository.

More information

e-pub ahead of print date: 23 August 2006
Published date: December 2006
Organisations: Faculty of Health Sciences

Identifiers

Local EPrints ID: 348739
URI: http://eprints.soton.ac.uk/id/eprint/348739
PURE UUID: 485d4e31-6e5f-4e6e-b31d-c0ceed8924b4

Catalogue record

Date deposited: 18 Feb 2013 16:52
Last modified: 16 Jul 2019 21:43

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×